

Date: 12th September 2024

Ref: CORP 2024 - 172

Dear xxx

Freedom of Information request: Treatment of Cancers (CORP 2024 – 172)

Thank you for your request for information which the Trust received on 23rd August 2024.

Your request and the response are contained within Appendix 1 below.

I trust this answers your request for information, however, should you not be satisfied with the information supplied or the process of supplying it, you have a right to complain and request a review. Please note that you must submit a request for a review within 40 days of the date of this letter.

You should forward your complaint to:

Mr Ian Bevan via FOI.VUNHST@wales.nhs.uk
Head of Information Governance
Velindre University NHS Trust
2, Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff / Caerdydd
CF15 7QZ

Should you wish to take your complaint further, if you are still unhappy with the decision after review, you can contact the:

Information Commissioner's Office - Wales
2nd Floor
Churchill House
Churchill Way
Cardiff
CF10 2HH
Telephone: 0330 414 6421
email: wales@ico.org.uk

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



Ymddiriedolaeth GIG
Prifysgol Felindre
Velindre University
NHS Trust




Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre
Velindre University NHS Trust Headquarters
2 Cwrt Charnwood
Heol Billingsley
Parc Nantgarw
Caerdydd/Cardiff
CF15 7QZ
Ffôn/Phone : (029) 20196161
<https://velindre.nhs.wales>

Yours sincerely

**Non Gwilym
Interim Director of Corporate Governance**

Velindre University NHS Trust
2 Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff
CF15 7QZ

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



APPENDIX 1

Caveats	Data captures all variant of drugs requested and date range has been adjusted to capture latest 3-months period data available
Notes:	Only leuprorelin was identified as being used as ADT out of the listed hormonal treatment drugs.

BREAST CANCER

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?


Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	20
1.2 Alpelisib (Piqray)	<6*
1.3 Fulvestrant (fulvestrant or Faslodex)	75
1.4 Palbociclib (Ibrance)	62
1.5 Ribociclib (Kisqali)	31
1.6 Capivasertib (Truqap)	0

*Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

Q2. How many patients received abemaciclib (Verzenios) for early breast cancer in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period for which data are available?

Number patients treated
6

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg. Velindre University NHS Trust is happy to receive communication in Welsh or English.



Q3. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period for which data are available?

Treatment intent	Number patients treated
3.1 Curative	0
3.2 Palliative	9
3.3 Not known / stated	0

Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of April 2024 and end of June 2024, or latest 3-month period available?


Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	0
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	<6*
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	0

*Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

Q5. How many patients were treated with Olaparib (Lynparza) for the following types of breast cancer in the 3 months between the start of April 2024 and end of June 2024?

Type of breast cancer	Number patients treated
5.1 all types of breast cancer	<6*
5.2 adjuvant treatment for early breast cancer	0

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg. Velindre University NHS Trust is happy to receive communication in Welsh or English.



*Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

PROSTATE CANCER

Q6. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
6.1 Abiraterone (Zytiga or generic abiraterone)	0
6.2 Apalutamide (Erleada)	0
6.3 Cabazitaxel (Jevtana or generic cabazitaxel)	20
6.4 Darolutamide (Nubeqa)	<6*
6.5 Enzalutamide (Xtandi)	0

*Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

Q7. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
Docetaxel for prostate cancer	52
Olaparib (Lynparza) for prostate cancer	0

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



Ymddiriedolaeth GIG
Prifysgol Felindre
Velindre University
NHS Trust



Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre
Velindre University NHS Trust Headquarters
2 Cwrt Charnwood
Heol Billingsley
Parc Nantgarw
Caerdydd/Cardiff
CF15 7QZ
Ffôn/Phone : (029) 20196161
<https://velindre.nhs.wales>

Q8. How many patients were treated with the following medicine combinations in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
8.1 Abiraterone (Zytiga or abiraterone) + Androgen Deprivation Therapy	0
8.2 Apalutamide (Erleada) + Androgen Deprivation Therapy	0
8.3 Darolutamide (Nubeqa) + Docetaxel + ADT	0
8.4 Enzalutamide (Zytiga) + Androgen Deprivation Therapy	0
8.5 Olaparib (Lynparza) + Abiraterone	0

Androgen Deprivation Therapy (ADT) = hormonal treatments, such as bicalutamide, leuprorelin, triptorelin, degarelix, flutamide

Q9. How many patients were treated with abiraterone for non-metastatic hormone sensitive prostate cancer in the 3 months between 1st April 2024 and 30th June 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
Abiraterone	0

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg. Velindre University NHS Trust is happy to receive communication in Welsh or English.

